E. Kaukel

6.9k total citations · 3 hit papers
49 papers, 5.1k citations indexed

About

E. Kaukel is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, E. Kaukel has authored 49 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Pulmonary and Respiratory Medicine, 20 papers in Oncology and 18 papers in Molecular Biology. Recurrent topics in E. Kaukel's work include Lung Cancer Research Studies (18 papers), Lung Cancer Treatments and Mutations (13 papers) and Cancer therapeutics and mechanisms (9 papers). E. Kaukel is often cited by papers focused on Lung Cancer Research Studies (18 papers), Lung Cancer Treatments and Mutations (13 papers) and Cancer therapeutics and mechanisms (9 papers). E. Kaukel collaborates with scholars based in Germany, United States and United Kingdom. E. Kaukel's co-authors include U. Gatzemeier, Christian Manegold, Michael Boyer, James T. Symanowski, Claude Denham, Salih Emri, Pierre Ruffiè, James J. Rusthoven, Clet Niyikiza and Paolo Paoletti and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

E. Kaukel

48 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

2003 2.3k citations Nicholas J. Vogelzang, James J. Rusthoven et al. Journal of Clinical Oncology profile →
Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group

2003 763 citations Frank V. Fossella, Jose R. Pereira et al. Journal of Clinical Oncology profile →
Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial

2007 706 citations U. Gatzemeier, A Płużańska et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by E. Kaukel

Since Specialization

Citations

This map shows the geographic impact of E. Kaukel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Kaukel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Kaukel more than expected).

Fields of papers citing papers by E. Kaukel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Kaukel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Kaukel. The network helps show where E. Kaukel may publish in the future.

Co-authorship network of co-authors of E. Kaukel

This figure shows the co-authorship network connecting the top 25 collaborators of E. Kaukel. A scholar is included among the top collaborators of E. Kaukel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Kaukel. E. Kaukel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma 2023 ·Journal of Clinical Oncology ·Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski, Claude Denham, E. Kaukel, Pierre Ruffiè, U. Gatzemeier, Michael Boyer, Salih Emri, Christian Manegold, Clet Niyikiza, Paolo Paoletti	18
2	Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer 2008 ·British Journal of Cancer ·Luis Paz‐Ares, Helen J. Ross, Mary O’Brien, A. Riviére, U. Gatzemeier, Joachim von Pawel, E. Kaukel, L Freitag, W. Digel, Helge Bischoff, Rosario García‐Campelo, Nicholas Iannotti, Pavel Reiterer, Isabel Bover, J Prendiville, Amy J. Eisenfeld, F. B. Oldham, B. Bandstra, Jack W. Singer, Philip Bonomi	125
3	Single-Agent Pemetrexed or Sequential Pemetrexed/Gemcitabine as Front-Line Treatment of Advanced Non-small Cell Lung Cancer in Elderly Patients or Patients Ineligible for Platinum-Based Chemotherapy: A Multicenter, Randomized, Phase II Trial 2007 ·Journal of Thoracic Oncology ·Cesare Gridelli, E. Kaukel, Vanesa Gregorc, Maria Rita Migliorino, Thomas Müller, Christian Manegold, Adolfo Favaretto, Andrea Martoni, Orazio Caffo, Alexander Schmittel, Antônio Rossi, Francesco Paolo Russo, Patrick Peterson, María del Mar Muñoz, Martin Reck	35
4	Effect of chemotherapy for advanced non-small cell lung cancer on patients’ quality of life 2006 ·Lung Cancer ·Chandra P. Belani, Jose R. Pereira, Joachim von Pawel, A Płużańska, Vera Gorbounova, E. Kaukel, K. Mattson, Rodryg Ramlau, Aleksandra Szczęsna, Panos Fidias, Michael Millward, Frank V. Fossella	48
5	Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: Quality of life and 6-years’-follow-up results from a randomised phase III trial 2006 ·Lung Cancer ·Martin Reck, Joachim von Pawel, (unknown), E. Kaukel, Karl-Matthias Deppermann, R. Bonnet, Kurt Ulm, (unknown), U. Gatzemeier	17
6	SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results 2004 ·Annals of Oncology ·E O’Brien, Heather Anderson, E. Kaukel, Kenneth J. O’Byrne, Marek Pawlicki, Joachim von Pawel, Martin Reck	111
7	Randomized Phase III Trial of Paclitaxel, Etoposide, and Carboplatin Versus Carboplatin, Etoposide, and Vincristine in Patients With Small-Cell Lung Cancer 2003 ·JNCI Journal of the National Cancer Institute ·Martin Reck, Joachim von Pawel, (unknown), E. Kaukel, Karl-Matthias Deppermann, R. Bonnet, Kurt Ulm, (unknown), U. Gatzemeier	60
8	Ifosfamide, carboplatin and etoposide combined with 41.8°C whole body hyperthermia for malignant pleural mesothelioma 2003 ·Lung Cancer ·(unknown), Ingmar Bruns, Anne M. Traynor, H. Ian Robins, K. Eberhardt, (unknown), E. Kaukel, (unknown), U. Gatzemeier, (unknown), Klaus Dalhoff, Eva‐Maria Ehlers, (unknown), (unknown), S. Hegewisch-Becker, S. Peters, G. Wiedemann	23
9	Total Pulmonary Vein Occlusion as a Consequence of Catheter Ablation for Atrial Fibrillation Mimicking Primary Lung Disease 2003 ·Journal of Cardiovascular Electrophysiology ·Sabine Ernst, Feifan Ouyang, Masahiko Goya, (unknown), Carsten Schneider, (unknown), Stefan Schwarz, (unknown), Klaus‐Michael Müller, Matthias Antz, E. Kaukel, Christian Kügler, Karl‐Heinz Kück	62
10	Long-term survival in SCLC after treatment with paclitaxel, carboplatin and etoposide—A phase II study 2002 ·Lung Cancer ·Martin Reck, (unknown), (unknown), E. Kaukel, (unknown), Joachim von Pawel, (unknown), U. Gatzemeier	8
11	Phase II trial of ZD0473 as second-line therapy in mesothelioma 2002 ·European Journal of Cancer ·Giuseppe Giaccone, Mary O’Brien, Michael Byrne, Martin Bard, E. Kaukel, Ben Smit	49
12	Lenograstim as Support for ACE Chemotherapy of Small-Cell Lung Cancer 2000 ·American Journal of Clinical Oncology ·U. Gatzemeier, J P Kleisbauer, P. Drings, E. Kaukel, Nikolaos Samaras, (unknown), F. Cardenal, G. Robinet, (unknown), Joachim von Pawel, (unknown)	25
13	A Randomized Trial with Mitomycin-C/Ifosfamide Versus Mitomycin-C/Vindesine Versus Cisplatin/Etoposide in Advanced Non-Small-Cell Lung Cancer 1991 ·American Journal of Clinical Oncology ·U. Gatzemeier, (unknown), Dieter K. Hossfeld, E. Kaukel, (unknown), (unknown)	15
14	A phase II study of pirarubicin in malignant pleural mesothelioma 1990 ·Cancer ·E. Kaukel, (unknown), (unknown), (unknown)	29
15	The new anthracycline THP-ADM (4′-0-tetrahydropyranyl-adriamycin) in the treatment of malignant pleuramesotheliomas 1986 ·Journal of Cancer Research and Clinical Oncology ·U. Gatzemeier, (unknown), E. Kaukel, (unknown), H Magnussen, (unknown)	2
16	[Effect of dopamine on the intrarenal cAMP concentration]. 1975 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·(unknown), (unknown), E. Kaukel	1
17	Basal cAMP in HeLa cells is protected from phosphodiesterase and does not turn over 1975 ·Biochemical and Biophysical Research Communications ·Helmuth Hilz, E. Kaukel, U. Wiegers, U. Fuhrmann	5
18	The significance of cyclic 3′5′-AMP for the euler-liljestrand mechanism 1974 ·Lung ·(unknown), E. Kaukel, (unknown), (unknown)	6
19	Divergent action mechanism of cAMP and dibutyryl cAMP on cell proliferation and macromolecular synthesis in HeLa S3 cultures 1973 ·Molecular and Cellular Biochemistry ·Helmuth Hilz, E. Kaukel	41
20	Permeation of dibutyryl cAMP into HeLa cells and its conversion to monobutyryl cAMP 1972 ·Biochemical and Biophysical Research Communications ·E. Kaukel, Helmuth Hilz	122

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact